Overview

A Clinical Study of KLH-2109 in Patients With Endometriosis

Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
To verify the non-inferiority of KLH-2109 to leuprorelin acetate in a double-blind manner in terms of efficacy in endometriosis patients with pelvic pain.
Phase:
PHASE3
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Treatments:
Leuprolide
linzagolix